Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced results from multiple analyses at The
Liver Meeting 2016, which provide additional evidence
supporting the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg
tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or
GT4-infected patient populations, including those who receive opioid
agonist therapy (OAT), are infected with chronic HCV GT1b, use proton
pump inhibitors (PPIs) or have moderate kidney disease.